Owens & Minor is focused on paying down debt and rethinking how it builds momentum in its “pure-play” Patient Direct business ...

Coliseum Capital, a ten-percent owner of Owens & Minor INC/VA/ (NYSE:OMI), has recently purchased shares of the company worth approximately $8.1 million. These purchases, executed between August 12 ...

UBS analyst Kevin Caliendo lowered the firm’s price target on Owens & Minor to $7 from $13 and keeps a Buy rating on the shares. Owens & Minor’s ...

Citigroup analyst Daniel Grosslight maintained Owens & Minor with a Buy and lowered the price target from $11 to $7. Baird ...

BofA analyst Allen Lutz lowered the firm’s price target on Owens & Minor to $4.70 from $7.50 and keeps an Underperform rating on the shares. The ...

Owens & Minor Inc (OMI) reports a 3.3% revenue increase while focusing on strategic divestitures and overcoming supply chain ...

Owens & Minor, Inc. faces financial distress with a 70% stock drop, weak margins, and strategic missteps. Click here to find out why OMI stock is a Hold.

Owens & Minor missed EPS estimates in Q2, but sales and EBITDA grew as it advanced plans to sell one of its segments.

Owens & Minor says it is in the final stages of selling its Products & Healthcare Services segment, says CEO Ed Pesicka.

Earlier in the day, Owens & Minor reported second-quarter adjusted earnings of $0.26 per share, missing the Street estimate by $0.02 per share. Its quarterly revenue rose 3.3% to $681.9M.

(OMI) on Monday reported a loss of $869.1 million in its second quarter. The Glen Allen, Virginia-based company said it had a ...

The company’s adjusted EBITDA from continuing operations increased to $96.6 million in the second quarter, compared to $91.1 million in the prior-year period. Owens & Minor has classified its Products ...